Source link : https://www.newshealth.biz/health-news/quads-frailty-and-the-future-evolving-frontline-strategies-in-multiple-myeloma/
Using quadruplet regimens with anti-CD38 monoclonal antibodies, such as daratumumab (Darzalex) or isatuximab (Sarclisa), has significantly advanced frontline therapy for both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma, according to data presented at the American Society of Hematology (ASH) annual meeting. MedPage Today brought together three expert leaders in the field: Moderator Joseph […]
Author : News Health
Publish date : 2024-12-20 15:36:21
Copyright for syndicated content belongs to the linked Source.